Mind Medicine Inc. (MNMD) has released an update.
Mind Medicine Inc. has announced successful Phase 2b trial results for its anxiety treatment, MM120, and received FDA Breakthrough Therapy Designation, underscoring its robust Q1 2024 financials with $252.3 million in cash reserves. The company’s advancements bode well for the future, with Phase 3 trials set for the second half of 2024 and ongoing development of treatments for autism and other conditions.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
